病例报告:Enfortumab vedotin诱导耐火DKA和多器官衰竭 - - 一种罕见的致命不良事件
Astha Koolwal Kapoor1, Carleton S Ellis2,3, Deepali Pandey2
1Department of Internal Medicine, Vassar Brothers Medical Center Nuvance Health, Poughkeepsie, NY, United States.
恩福图马布维多丁 (EV) 可以在尿路癌患者中引起严重的糖尿病酸性脂肪酸症 (DKA). 本案例报告强调了耐火DKA,并审查了类似的文献,以获得更好的管理策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 局部晚期或转移性尿道癌 (UC) 的治疗选择有限.
- 恩福图马布维多丁 (EV) 是一种已批准的UC治疗方法,提供了一种新的治疗途径.
- 尽管有效,但EV可能会导致严重的不良事件.
更多相关视频
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
12:41Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
相关概念视频
Drug Toxicity: Overview
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions
Drug toxicity: Idiosyncratic Reactions
Diabetic Ketoacidosis l: Introduction
Diabetic Ketoacidosis ll: Pathophysiology
